Previous studies indicated that among other neurons, those in the hypothalamus that secrete the neuropeptide orexin simultaneously control both food intake and energy expenditure. 3 This prompted ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The new data provides evidence of the benefit of Idorsia’s dual orexin receptor antagonist, daridorexant (QUVIVIQ™), at a daily dose of 50 mg, in patients aged >=55 years with chronic insomnia and ...

Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a "safety signal" in the study. The future of the programme seems to be in ...

In 1998, we purified a novel neuropeptide orexin and showed that this peptide plays pivotal roles in the regulation of appetite and sleep. In this ERATO project, we showed that the administration of ...